OBJECTIVES : To compare the annual cost of prophylaxis treatment with a bypass agent for a pediatric patient with Severe Hemophilia A and Inhibitors versus annual cost of prophylaxis treatment with a bispecific monoclonal antibody from the perspective of the third payer.

METHODS : The direct comparison of drug costs was made by comparing a one-year prophylactic treatment with APCC bypass agent in a 28 kg pediatric patient with Severe Hemophilia A and Inhibitors with a treatment scheme of 35 IU / kg intravenously 3 times per week versus the estimated cost of one-year prophylactic treatment with Emicizumab (bispecific monoclonal antibody) with a loading dose of 3 mg / kg every week for the first 4 weeks and a maintenance dose of 3 mg / kg weight every two weeks subcutaneously.

RESULTS : The cost of a one-year prophylactic treatment with APCC for a pediatric patient in Peru was $2773.772 USD. The estimated cost of one-year prophylactic treatment with Emicizumab for a pediatric patient with HAI was $ 119,496 USD.

CONCLUSIONS : Emicizumab generates an annual saving for the Peru health system of $ 154,276 USD in direct comparison of medications costs regarding the use of APCC for prophylaxis of a pediatric patient with Severe Hemophilia A and Inhibitors.